Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback